Western Wealth Management LLC Acquires 2,115 Shares of Stryker Corporation $SYK

Western Wealth Management LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 33.2% in the first quarter, HoldingsChannel reports. The fund owned 8,493 shares of the medical technology company’s stock after acquiring an additional 2,115 shares during the period. Western Wealth Management LLC’s holdings in Stryker were worth $2,791,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. VanderPol Investments L.L.C. grew its holdings in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC lifted its holdings in shares of Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC boosted its position in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp boosted its position in shares of Stryker by 1.2% in the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SYK. JPMorgan Chase & Co. reduced their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. Finally, UBS Group initiated coverage on Stryker in a research report on Tuesday. They issued a “buy” rating and a $400.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $387.88.

Stryker Stock Down 6.2%

SYK stock opened at $326.41 on Friday. The stock has a market capitalization of $125.13 billion, a P/E ratio of 33.82, a P/E/G ratio of 2.23 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $401.99. The business has a fifty day moving average price of $317.28 and a 200-day moving average price of $334.92.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 24.06% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. Stryker’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.